Switch study from TDF-containing ART to E/C/F/TAF in virologically suppressed adults aged 60 years or older with HIV-1

Phase 3, randomised, open-label trial of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoints: Percent change from baseline to Week 48 in spine bone mineral density and Percent change from baseline to Week 48 in hip bone mineral density. Started Sep 2015; status: completed.